Fig. 1: Study design of the 3 experiments.
From: Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates
In the first experiment of pharmacokinetic (PK), n = 4 animals were treated with favipiravir (FPV) for 14 days. In the second experiment, n = 12 were either treated or received placebo, and were challenged with 106 PFU of Zika virus (ZIKV) three days after treatment initiation. In the third experiment, n = 30 animals were either treated or received a placebo, and were challenged with 106 PFU of SARS-CoV-2 two days after treatment initiation. Hatched area indicates FPV treatment without viral exposure. Colored areas indicate FPV dosing regimens; cyan: 200 mg/kg twice a day (BID) administered intravenously (i.v) on day −2 followed by 100 mg/kg BID administered subcutaneously (s.c); magenta: 250 mg/kg BID i.v. on day −3 (ZIKV) or −2 (SARS-CoV-2) followed by 150 mg/kg BID s.c.; yellow: 250 mg/kg BID i.v. on day −2 followed by 180 mg/kg BID sc. Untreated animals received NaCl 0.9% solution as placebo.
